



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

5737 04 JAN 21 2004

Re: Lumigan
Docket No.: 03E-0037

The Honorable James E. Rogan
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

JAN 14 2004

Dear Director Rogan:

This is in regard to the application for patent term extension for U.S. Patent No. 5,688,819, filed by Allergan, under 35 U.S.C. section 156 *et seq.* We have reviewed the dates contained in the application and have determined the regulatory review period for Lumigan, the human drug product claimed by the patent.

The total length of the regulatory review period for Lumigan is 1,967 days. Of this time, 1,787 days occurred during the testing phase and 180 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: October 29, 1995.

The applicant claims October 28, 1995, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was October 29, 1995, which was thirty days after FDA receipt of the IND.

2. The date the application was initially submitted with respect to the human drug product under section 505(b) of the Federal Food, Drug, and Cosmetic Act: September 18, 2000.

FDA has verified the applicant's claim that the new drug application (NDA) for Lumigan (NDA 21-275) was initially submitted on September 18, 2000.

3. The date the application was approved: March 16, 2001.

FDA has verified the applicant's claim that NDA 21-275 was approved on March 16, 2001.


03E-0037

LET 3

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,



Jane A. Axelrad

Associate Director for Policy
Center for Drug Evaluation and Research

cc: Robert J. Baran
Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612